APOLLOMICS INC (APLM) Stock Price, Quote, News and Overview
NASDAQ:APLM - Nasdaq - KYG0411D1079 - Common Stock - Currency: USD
APLM Quote, Performance and Key Statistics
APOLLOMICS INC
NASDAQ:APLM (1/31/2025, 8:11:10 PM)
8.5
-0.44 (-4.92%)
The current stock price of APLM is 8.5 USD. In the past month the price decreased by -12.82%. In the past year, price decreased by -89.51%.
APLM Latest News, Press Releases and Analysis
Apollomics 公布在中国对复发或难治性急性髓系白血病患者进行的 Uproleselan III 期桥接试验主要结果
加利福尼亚州福斯特城, Dec. 21, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (简称 “Apollomics” 或 “公司”)...
Apollomics 公布 Uproleselan 在中國治療復發或難治性急性髓系白血病患者的第 3 期銜接性試驗的主要結果
福特斯城，加州, Dec. 21, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (「Apollomics」或「該公司」) 是一家後期臨床生物製藥公司，開發多種腫瘤候選藥物以解決難治性和對治療有抗藥性的癌症。該公司今日公布了其藥物...
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a clinical-stage biopharmaceutical company...
APLM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.17 | 324.98B | ||
| AMGN | AMGEN INC | 14.85 | 153.42B | ||
| GILD | GILEAD SCIENCES INC | 21.94 | 121.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 905.25 | 118.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.81 | 73.95B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.99B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.67B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.98B | ||
| NTRA | NATERA INC | N/A | 23.36B | ||
| BIIB | BIOGEN INC | 8.81 | 20.97B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.86B |
Related stock screener links
About APLM
Company Profile
Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company is headquartered in Foster City, California and currently employs 45 full-time employees. The company went IPO on 2021-11-26. The firm uses both targeted, immuno-oncology, and other approaches to address a range of cancer indications, such as acute myeloid leukemia, lung cancer, brain cancer, and other solid tumors. The product candidates in its pipeline are categorized into three groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumour inhibitors, anti-cancer enhancers, and immuno-oncology drugs. Its advanced product candidate is vebreltinib (APL-101), a potent, oral active, highly selective c-Met inhibitor. Its anti-cancer enhancer product candidates include uproleselan (APL-106) and are antagonists of a cell adhesion receptor called E-selectin. Its immuno-oncology product candidates consist of APL-501, APL-502, APL-801 and APL-810. Its other product candidates include APL-122, APL-102, and APL-108.
Company Info
APOLLOMICS INC
989 East Hillsdale Blvd, Ste 220
Foster City CALIFORNIA US
Employees: 45
Company Website: https://www.apollomicsinc.com
Investor Relations: https://ir.apollomicsinc.com/
Phone: 16502094055
APLM FAQ
What is the stock price of APLM?
The current stock price of APLM is 8.5 USD.
What is the symbol for APOLLOMICS INC stock?
The exchange symbol of APOLLOMICS INC is APLM and it is listed on the Nasdaq exchange.
On which exchange is APLM stock listed?
APLM stock is listed on the Nasdaq exchange.
Is APLM a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for APLM, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of APLM.
Does APLM stock pay dividends?
APLM does not pay a dividend.
What is the Price/Earnings (PE) ratio of APLM?
APLM does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.93).
What is the Short Interest ratio of APLM stock?
The outstanding short interest for APLM is 1.85% of its float.
APLM Technical Analysis
APLM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to APLM. APLM may be in some trouble as it scores bad on both profitability and health.
APLM Financial Highlights
Over the last trailing twelve months APLM reported a non-GAAP Earnings per Share(EPS) of -1.93. The EPS decreased by -3757.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -311.63% | ||
| ROE | -418.59% | ||
| Debt/Equity | 0.01 |
APLM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to APLM. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 99.53% and a revenue growth -100% for APLM